<DOC>
	<DOCNO>NCT02351102</DOCNO>
	<brief_summary>The purpose study determine whether Valacyclovir treatment , administer pregnancy proven primary maternal Cytomegalovirus ( CMV ) infection , reduce fetal transmission rate prevent fetal injury case fetal infection .</brief_summary>
	<brief_title>Valacyclovir Prevent Vertical Transmission Cytomegalovirus After Maternal Primary Infection During Pregnancy</brief_title>
	<detailed_description>A randomized , double-blind , placebo-controlled study . Participants : Pregnant woman 18 year age serologically proven , primary CMV infection first trim Intervention : After inform consent randomization , participant treatment group receive Valacyclovir dose 8 g/d . Participants control group receive amount daily pill contain placebo . Treatment continue amniocentesis , determine fetus infect .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<mesh_term>Valacyclovir</mesh_term>
	<mesh_term>Acyclovir</mesh_term>
	<criteria>Pregnant woman 18 year age serologically proven , primary CMV infection first trim pregnancy periconceptionally Patients preexist liver disease , renal dysfunction , bone marrow suppression sensitivity Acyclovir exclude study patient receive antiviral therapy prior study .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Congenital CMV</keyword>
	<keyword>Congenital Cytomegalovirus</keyword>
</DOC>